Subscribe
Biosimilar therapy for breast cancer, zoledronic acid for bone metastases, the future of Obamacare under Donald Trump, and more

JAMA Editor’s Summary

Biosimilar therapy for breast cancer, zoledronic acid for bone metastases, the future of Obamacare under Donald Trump, and more

Editors’ Summary by Phil B. Fontanarosa, MD, MBA, Executive Editor of JAMA, the Journal of the American Medical Association, for the
January 3, 2017

Biosimilar therapy for breast cancer, zoledronic acid for bone metastases, the future of Obamacare under Donald Trump, and more

Editors’ Summary by Phil B. Fontanarosa, MD, MBA, Executive Editor of JAMA, the Journal of the American Medical Association, for the January 3, 2017 issue

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Proudly supported by:

cover
Cultivating Resilience During Times of Crisis and Existential Threat Keith interviews Dr. Chris Recinos, the CEO and founder of Nurse Leader Network, regarding mental health, adaptive and maladaptive mechanisms of resilience, and conscious self-development.